An interventional study of Standardized Oral Hygiene Education and Plaque-Disclosing Tablet Visual Reinforcement in Gingivitis and Periodontal Diseases, sponsored by Ezgi Sila Taskaldiran. Completed at 1 site in Turkey (Türkiye). Open to participants aged 10 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Ezgi Sila Taskaldiran · Not applicable, Interventional, and Prevention
This randomized controlled clinical trial evaluated whether a single at-home use of a plaque-disclosing tablet, as visual reinforcement following oral hygiene education, provides additional short-term benefits in plaque control and gingival health in children aged 10-14 years.
A total of 53 participants were randomized to a test group or a control group. All participants received plaque disclosure and standardized oral hygiene instruction including the modified Bass toothbrushing technique. Participants in the test group were additionally provided with one plaque-disclosing tablet to use on the fourth day after the initial visit, whereas the control group received no additional intervention. Plaque and gingival indices were recorded at baseline and again at the end of the first week.
631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.
This study's enrollment of 53 is below the median of 66 across 507 interventional studies indexed under Gingivitis.
Browse Gingivitis studies →This is the only study on the registry with Ezgi Sila Taskaldiran as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard oral hygiene education + baseline plaque disclosure + single plaque-disclosing tablet reinforcement on day 4.
Behavioral: Standardized Oral Hygiene Education · Behavioral: Plaque-Disclosing Tablet Visual Reinforcement
Standard oral hygiene education + baseline plaque disclosure only.
Behavioral: Standardized Oral Hygiene Education
Participants received plaque disclosure followed by individualized visual feedback and standardized oral hygiene instruction using the modified Bass toothbrushing technique.
Participants in the experimental arm were provided with one plaque-disclosing tablet and instructed to use it at home on the fourth day after the initial visit as a single visual reinforcement of the oral hygiene education.
Change in Quigley-Hein Plaque Index
Plaque accumulation was assessed using the Quigley-Hein Plaque Index at the full-mouth level and separately for the incisor, canine, premolar, and molar regions. Scores were recorded at baseline and at the end of the first week. Lower scores indicate lower plaque accumulation.
Time frame: From enrollment to the end of treatment at 1 week
Change in Gingival Index
Gingival health was assessed using the Gingival Index at the full-mouth level. Scores were recorded at baseline and at the end of the first week. Lower scores indicate better gingival health.
Time frame: From enrollment to the end of treatment at 1 week
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.